Cefaclor Anhydrous

Summary

Cefaclor Anhydrous (CHEMBL680) is an approved small-molecule antibacterial drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 367.8 Da · C15H14ClN3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL680
Name	Cefaclor Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	51039
ChEBI	CHEBI:3478
Molecular formula	C15H14ClN3O4S
Molecular weight	367.8
InChIKey	QYIYFLOTGYLRGG-GPCCPHFNSA-N

SMILES: C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl

IUPAC name: (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.

Pharmacological roles (ChEBI): antibacterial drug, drug allergen.

Also known as: Cefaclor anhydrous, cefaclor, Cefaclor, SID29215008, SID855765, CEFACLOR, SID144204431, SID170464885, Loracarbef, C0164873, CEFACLOR ANHYDROUS

Parent form; salt/anhydrous children: CHEMBL1201018

Patent coverage: 8,967 distinct patent families (34,121 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Streptokinase A, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Solute carrier family 15 member 2, Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1, Menin/Histone-lysine N-methyltransferase MLL, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10520	6.33	EC50	465	nM	CHEMBL_ACT_4897761
A8B2U2	5.6	Potency	2506	nM	CHEMBL_ACT_4599159
CTDSP1	5.14	IC50	7184	nM	CHEMBL_ACT_6963693

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05398679	PHASE4	RECRUITING	Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).